Oncodrivers in Advanced or Metastatic NSCLC: Current and Future Standards of Care - Episode 6
Use of ROS1-Targeting Agents in Clinical Practice
Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.
Panelists highlight how real-world experience mirrors clinical trial outcomes, demonstrating substantial benefits with targeted therapy when patients are appropriately selected through molecular testing. They emphasize that early testing is essential to avoid delays in initiating treatment and ensuring optimal response.
Challenges in real-world implementation include limited access to next-generation sequencing and variations in testing quality across institutions. Panelists discuss how multidisciplinary collaboration and patient education can mitigate these disparities. They also emphasize the importance of proactive monitoring for toxicity and adherence support.
Ultimately, they agree that the translation of evidence-based ROS1 therapy into community practice requires standardized molecular testing, strong communication across care teams, and ongoing evaluation of outcomes to guide continuous improvement in care delivery.
Related Content:
